Barclays Maintains Overweight on Replimune Group, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Replimune Group (NASDAQ:REPL) and raises the price target from $13 to $17.
June 07, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Replimune Group and raises the price target from $13 to $17.
The increase in the price target from $13 to $17 by a reputable analyst at Barclays is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100